We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News   May 28, 2020

 
IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Credit: Pixabay

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Mologic’s COVID-19 Rapid Antigen Self-Test Selected by NIH for RADx Initiative Funding

Product News

Mologic has announced that its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics initiative launched by the U.S. National Institutes of Health. The initiative aims to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing.

READ MORE

Avacta Announces Distribution Agreement With ABCAM plc

Product News

Avacta Group plc has announced that it has entered into a global distribution agreement with ABCAM plc to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

READ MORE

Ceryx Medical Appoints Chas Taylor as Chairman

Product News

Chas Taylor has been appointed as Chairman at Ceryx Medical. Taylor brings with him decades of experience in developing and leading medical device companies.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE